Key result
Mucopolysaccharidosis type III was associated with impaired mean global longitudinal strain compared to controls in both pediatric (MD 2.25; P=0.009) and adult (MD 2.64; P=0.007) patients.
Why the study?
Mucopolysaccharidosis type III is primarily characterized by neurocognitive decline with limited somatic disease, and only few reports have addressed cardiac disease.
What is the prevalence and nature of subclinical cardiac disease in patients with Mucopolysaccharidosis type III compared to matched controls?
Cross-Sectional (n=30)
What is the prevalence and nature of subclinical cardiac disease in patients with Mucopolysaccharidosis type III compared to matched controls?
Patients with Mucopolysaccharidosis type III exhibit early, subclinical left ventricular dysfunction and valvular abnormalities that appear to progress with age.
May warrant cardiac surveillance in MPS III; leaves open whether GLS predicts outcomes in longitudinal studies.
Mucopolysaccharidosis type III (MPS III; Sanfilippo disease) is primarily characterized by neurocognitive decline with limited somatic disease. Only few reports addressed cardiac disease (CD) in MPS III. We investigated the prevalence of CD in a relatively large cohort of patients. In this cross-sectional study, extensive echocardiographic studies were performed in 30 MPS III patients (16 patients <18 years), all without clinical symptoms of CD. Results were compared to data from matched controls. The mean global longitudinal strain on speckle-tracking echocardiography (STE) was impaired in both pediatric and adult patients vs controls (resp. -18.4% vs -20.7%; mean difference 2.25, 95% CI 0.61-3.89, P = 0.009 and -16.9% vs -19.5%; mean difference 2.64, 95% CI 0.78-4.49, P = 0.007), indicating early systolic dysfunction. Left ventricle ejection fraction (LVEF) was normal in pediatric patients and (slightly) impaired in adult patients vs controls (48.7% vs 55.8%, P = 0.002). Tissue Doppler imaging (TDI) showed significantly slower early diastolic velocities (e') compared to controls indicative for diastolic dysfunction. Furthermore, mitral and aortic valve abnormalities were prevalent (43% and 33% of patients, respectively). Finally, 15.6% of the patients had a first-degree atrioventricular block on electrocardiography (ECG). The impaired STE reveals early, subclinical LV dysfunction which is supported by results of TDI. In addition, mild valvular disease and ECG abnormalities are prevalent. The lowered LVEF in adult patients suggests that the LV dysfunction is progressive, and may ultimately lead to clinical myocardial disease when patients live longer due to an effective disease-modifying treatment of which a number of options are now in clinical trials.
No takes yet. Share an insight, caveat, or question.
Nijmeijer et al. (2019) conducted a cross-sectional in Mucopolysaccharidosis type III (n=30). Mucopolysaccharidosis type III vs. matched controls was evaluated on mean global longitudinal strain on speckle-tracking echocardiography in pediatric patients (MD 2.25, 95% CI 0.61-3.89, p=0.009). Mucopolysaccharidosis type III was associated with impaired mean global longitudinal strain compared to controls in both pediatric (MD 2.25; P=0.009) and adult (MD 2.64; P=0.007) patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: